Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 33-42, February 2010

Novel therapeutic approaches to the treatment of metastatic breast cancer

  • Yolanda Fernández

      Affiliations

    • Hospital Universitario Central de Asturias, Oviedo, Spain
    • Corresponding Author InformationCorresponding author. Address: Medical Oncology Service, Hospital Universitario Central de Asturias, Calle Celestino Villamil, s/n. 33006-Oviedo, Spain. Tel.: +34 985 108 000; fax: +34 985 108 015.
  • ,
  • Juan Cueva

      Affiliations

    • Complexo Hospitalario Universitario de Santiago, A Coruña, Spain
  • ,
  • Andrés G. Palomo

      Affiliations

    • Hospital de León, León, Spain
  • ,
  • Manuel Ramos

      Affiliations

    • Centro Oncológico Regional, A Coruña, Spain
  • ,
  • Ana de Juan

      Affiliations

    • Hospital Marqués de Valdecilla, Santander, Spain
  • ,
  • Lourdes Calvo

      Affiliations

    • Complexo Hospitalario Universitario Juan Canalejo, A Coruña, Spain
  • ,
  • Jesús García-Mata

      Affiliations

    • Complexo Hospitalario de Ourense, Ourense, Spain
  • ,
  • Paula García-Teijido

      Affiliations

    • Hospital Universitario Central de Asturias, Oviedo, Spain
  • ,
  • Ignacio Peláez

      Affiliations

    • Hospital de Cabueñes, Gijón, Spain
  • ,
  • Laura García-Estévez

      Affiliations

    • Centro Integral Oncológico “Clara Campal”, Madrid, Spain

Received 2 July 2009; received in revised form 30 September 2009; accepted 2 October 2009. published online 02 November 2009.

Abstract 

Metastatic breast cancer is ultimately an incurable disease, although recent data have shown that its incidence is decreasing and that patients with metastatic breast cancer live longer. This improvement in survival seems to be linked with the introduction of new therapeutic agents, novel combinations of existing therapies and targeted therapies. Our increasing understanding of the molecular biology of metastatic disease has allowed the development of therapies aimed at specific molecular targets. Some of these have already been approved for the treatment of metastatic breast cancer in combination with cytotoxics, and others have shown promising results regarding disease-free survival, overall response rates and time to disease progression. Given the enormous amount of information about drug discovery in cancer, it is important to be familiar with the present state of the treatment of metastatic breast cancer. The purpose of this review is to provide an update on the development of some of the most promising novel agents and treatment strategies in metastatic breast cancer.

Keywords: Novel, Targeted, Metastatic breast cancer, Cytotoxic

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0305-7372(09)00142-X

doi:10.1016/j.ctrv.2009.10.001

Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 33-42, February 2010